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http://dx.doi.org/10.1016/j.ccell.2015.05.010SUMMARYWe report the preclinical evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor.
Compared with other clinically available ALK inhibitors, PF-06463922 displayed superior potency against
all known clinically acquired ALK mutations, including the highly resistant G1202R mutant. Furthermore,
PF-06463922 treatment led to regression of EML4-ALK-driven brainmetastases, leading to prolongedmouse
survival, in a superior manner. Finally, PF-06463922 demonstrated high selectivity and safety margins in a
variety of preclinical studies. These results suggest that PF-06463922will be highly effective for the treatment
of patients with ALK-driven lung cancers, including those who relapsed on clinically available ALK inhibitors
because of secondary ALK kinase domain mutations and/or brain metastases.INTRODUCTION
The clinical success of targeting oncogenic tyrosine kinases
that are genetically altered through activating mutations, gene
translocations, or gene amplification has launched a new era
of cancer therapy (Weinstein, 2002). However, acquired resis-
tance is a major limitation to the efficacy of tyrosine kinase inhib-
itors (TKIs) in the clinic (Bagrodia et al., 2012; Lackner et al.,
2012; Rosenzweig, 2012). Crizotinib, a small-molecule inhibitor
of the MET, ALK, and ROS1 tyrosine kinases, is highly active in
lung cancers harboring chromosomal rearrangements of ALK
or ROS1. In ALK-positive non-small-cell lung cancer (NSCLC)
patients, crizotinib demonstrated an objective response rate ofSignificance
Though the development of ALK inhibitors has changed the
relapse. Here, we demonstrate the superior properties of the
clinically available ALK inhibitors. PF-06463922 addresses two
tations and brain metastasis. Superior potency, selectivity, an
in its ability to achieve potent inhibition of all tested ALK resis
metastasis, while having robust safetymargins in preclinical stu
cer in both the refractory and the frontline settings.
70 Cancer Cell 28, 70–81, July 13, 2015 ª2015 Elsevier Inc.about 60% and a median progression-free survival of approxi-
mately 8 to 11 months (Camidge et al., 2012; Gerber and Minna,
2010; Kwak et al., 2010; Shaw et al., 2013; Solomon et al.,
2014c). Similar to the experience with other TKIs, several resis-
tance mechanisms have been observed in patients who relapse
on crizotinib. These resistance mechanisms include secondary
ALK kinase domain mutations (Choi et al., 2010; Doebele et al.,
2012; Katayama et al., 2011, 2012; Sasaki et al., 2011); ALK
gene amplification (Doebele et al., 2012; Katayama et al., 2012;
Kim et al., 2013); bypass downstream signaling via EGFR
(Katayama et al., 2012; Sasaki et al., 2011; Tanizaki et al.,
2012), KIT (Katayama et al., 2012), SRC (Crystal et al., 2014),
or IGF-1R (Lovly et al., 2014); and pharmacological resistancecourse of treatment in NSCLC patients, tumors invariably
next-generation ALK inhibitor PF-06463922 compared with
major mechanisms of clinical relapse, ALK resistance mu-
d physicochemical properties of PF-06462922 are reflected
tance mutations, to penetrate the CNS, and to regress brain
dies. PF-06463922 has the potential to treat ALK-driven can-
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Figure 1. PF-06463922 Is a Potent Inhibitor
of Wild-Type ALK and Crizotinib-Resistant
ALK Mutants
(A) PF-06463922 in biochemical kinase assays
with the indicated recombinant ALK kinase
domain constructs. Ki values are geometric means
with 95% confidence intervals for n independent
measurements.
(B) Biochemical kinase activity of recombinant
human wild-type ALK kinase domain treated with
the indicated concentrations of PF-06463922,
crizotinib, ceritinib, and alectinib. The kinase ac-
tivity was assayed by a microfluidic mobility shift
assay.
(C) IC50 values of PF-06463922, crizotinib,
ceritinib, and alectinib on ALK phosphorylation
(left) and cell viability (right) across different Ba/F3
cell lines expressing wild-type or mutated EML4-
ALK relative to parental interleukin-3-dependent
Ba/F3 cells.
Values are presented as mean ± SD (n = 3).
See also Figure S1 and Table S1.due to sub-optimal CNS exposure (Costa et al., 2011; Gandhi
et al., 2013; Maillet et al., 2013; Weickhardt et al., 2012). Roughly
30% of crizotinib-refractory tumors have been shown to
harbor resistance mutations in the ALK kinase domain, includ-
ing G1269A, L1196M, C1156Y, L1152R, S1206Y, 1151Tins,
G1202R, and F1174L (Gainor and Shaw, 2013). Although crizoti-
nib has shown clinical activity against brain metastases (Costa
et al., 2013; Kaneda et al., 2013; Kinoshita et al., 2013; Takeda
et al., 2013), progression in the brain is particularly common in
relapsed patients (Costa et al., 2015; Weickhardt et al., 2012).
Recently, the second-generation ALK inhibitors ceritinib and
alectinib have been approved for use in crizotinib-relapsed
ALK-fusion-positive NSCLC patients in the United States and
for ALK-fusion-positive crizotinib-naive NSCLC patients in
Japan, respectively (Chen et al., 2013; Gadgeel et al., 2014; Ki-
noshita et al., 2012; Shaw et al., 2014a). Although both ALK in-
hibitors show efficacy in these settings, resistance to both of
these inhibitors has emerged. In the case of ceritinib, relapsed
tumors often express the ALK mutant G1202R (Friboulet et al.,
2014). In the case of alectinib, in addition to G1202R, two ALK
resistance mutations (V1180L and I1171T) have been observed
(Ignatius Ou et al., 2014; Katayama et al., 2014). Some ALK mu-
tants such as G1202R confer high-level resistance to all clini-
cally available ALK inhibitors (Friboulet et al., 2014; Ignatius
Ou et al., 2014; Shaw and Engelman, 2013). Both ceritinib and
alectinib have demonstrated activity in brain metastases of
crizotinib-relapsed patients. A phase 1 and 2 clinical trial ofCancer Cell 28, 7alectinib showed a CNS response rate
of 52% (Gadgeel et al., 2014). Despite
the observed CNS activity with these
agents, it remains common for patients
to relapse with CNS progression. A full
understanding of the activity of clinically
available ALK inhibitors on brain metas-
tases is still emerging, and we provide
a glimpse into mechanisms for their
resistance here.We initiated a drug discovery program with the goal of devel-
oping a next-generation ALK inhibitor that is more potent and
selective than other known ALK inhibitors (including current
second-generation inhibitors), capable of inhibiting all known
resistant ALK mutants and able to penetrate the blood-brain
barrier (BBB) to achieve therapeutic CNS drug concentrations.
PF-06463922, an ATP-competitive small-molecule inhibitor of
ALK/ROS1, was successfully discovered by the optimization of
physicochemical properties guided by structure-based drug
design (Johnson et al., 2014). Here we investigate the preclinical
antitumor activity of PF-06463922 in both subcutaneous and
intracranial tumor models.
RESULTS
PF-06463922 Has Sub-nanomolar Biochemical
and Nanomolar Cellular Potency against Wild-Type
and Crizotinib-Resistant ALK Mutants
PF-06463922 is a potent, reversible, ATP-competitive inhibitor of
recombinant ALK kinase (Figure S1A). In biochemical assays,
PF-06463922 inhibited the catalytic activity of recombinant
human wild-type ALK with a mean Ki of <0.07 nM (Figure 1A).
In addition, PF-06463922 showed a range of mean Ki values
of <0.1 to 0.9 nM against the following crizotinib-resistant ALK
mutants: L1196M, G1269A, 1151Tins, F1174L, C1156Y,
L1152R, and S1206Y. PF-06463922 was more potent than
crizotinib, ceritinib, and alectinib against wild-type ALK in0–81, July 13, 2015 ª2015 Elsevier Inc. 71
biochemical studies (Figure 1B). In addition to its high potency
against ALK, PF-06463922 has previously demonstrated sub-
nanomolar cell potency against ROS1 (Zou et al., 2015) and
demonstrated >100-fold selectivity versus non-target kinases,
relative to the ALKL1196M gatekeeper mutant, for >95% of the
206 kinases tested (Johnson et al., 2014).
To directly compare the potencies of PF-06463922, crizotinib,
ceritinib, and alectinib in cell assays, NIH 3T3 and Ba/F3
cells were engineered to express either wild-type or the crizoti-
nib-resistant mutants 1151Tins, L1152R, C1156Y, L1196M,
G1269A, G1202R, F1174L, or S1206Y (Figures 1C and S1B;
Table S1). We observed a strong correlation between drug con-
centrations required to inhibit ALK phosphorylation and those
needed to block ALK-dependent cell proliferation (Figure 1C).
PF-06463922 was the most potent inhibitor against all clinically
relevant crizotinib-, ceritinib- and/or alectinib-resistant ALK
mutants. PF-06463922 showed strong ALK phosphorylation
potency against the L1196M (half maximal inhibitory concen-
tration [IC50] = 15–43 nM) and G1269A (IC50 = 14–80 nM) ALK
mutants, which are two of the most frequently detected crizoti-
nib-resistant mutations observed in the clinic (Doebele et al.,
2012; Kim et al., 2013). Furthermore, PF-06463922 demon-
strated potent ALK phosphorylation activity against the 1151Tins
(IC50 = 38–50 nM) and G1202R (IC50 = 77–113 nM) ALK mutants
that confer a high level of resistance to all second-generation
ALK inhibitors (Katayama et al., 2012; Shaw and Engelman,
2013).
PF-06463922 Inhibits ALK-Dependent Cell
Growth In Vitro
The activity of PF-06463922 on cell viability and intracellular
signaling was examined in H3122 and H2228 ALK-positive
lung cancer cell lines. In addition, we examined H3122 cells
engineered to overexpress the crizotinib-resistant ALK mutants
G1269A and L1196M. Similar to the Ba/F3 cell model, in these
cell lines, PF-06463922 was greater than 30-fold more potent
than crizotinib with respect to suppressing ALK-dependent
signaling and inhibiting cell growth and inducing apoptosis
(Figures 2A–2E and S2A–S2D; Table S1). Furthermore, the cell
viability of in vitro-derived alectinib-resistant H3122 cells, which
contain an endogenous V1180L ALK mutation (Katayama et al.,
2014), was sensitive to PF-06463922 via potent inhibition of
ALK signaling (Figures 2F and S2E).
The efficacy of PF-06463922 was also examined in cell lines
derived from patients with acquired resistance to crizotinib, cer-
itinib, or alectinib. These cells lines, SNU2535, MGH021-5, and
MGH056-1, harbor endogenous EML4-ALKG1269A, SQSTM1-
ALKG1202R, and EML4-ALKI1171T mutations, respectively. PF-
06463922 exhibited significantly greater cell growth inhibitory
potency in these cell lines compared with crizotinib. Cell growth
IC50 values for PF-06463922 were 47, 63, and 23 nM, respec-
tively, compared with 3,240, 1,046, and 271 nM, respectively,
for crizotinib (Figures 2G–2I). These cell growth IC50 values
correlated closely with the drugs’ abilities to inhibit ALK phos-
phorylation and downstream signaling in these cells (Figures
S2F–S2H). Overall, in both the patient-derived and engineered
cell lines, PF-06463922 consistently showed greater potency in
inhibiting ALK phosphorylation and cell viability compared with
clinically available ALK inhibitors.72 Cancer Cell 28, 70–81, July 13, 2015 ª2015 Elsevier Inc.PF-06463922Exhibits Potent Antitumor Efficacy In Vivo,
and Its Pharmacokinetic-Pharmacodynamic
Relationship in These Models
PF-06463922 was evaluated for its efficacy against subcutane-
ous growth of parental H3122 EML4-ALKWT and engineered
H3122 EML4-ALKL1196M, EML4-ALKG1269A, and NIH 3T3
EML4-ALKG1202R tumors (Figures 3A–3D). In these experiments,
PF-06463922 was administered by subcutaneous pump infu-
sion, which better mimics the predicted human pharmacokinetic
(PK) profile than oral dosing in mice (data not shown). Treatment
with PF-06463922 led to a dose-dependent antitumor effect
ranging from tumor growth inhibition (TGI) to tumor regression.
The effect on tumor growth was consistent with its ability to
dose-dependently inhibit ALK phosphorylation. Amaximal effect
of >95% inhibition of ALK phosphorylation was achieved in
each of themodels, and this resulted in tumor regression ranging
from 35% to 77% (Figure 3; Table S2). Of note, PF-06463922
significantly inhibited tumor growth in crizotinib-resistant models
harboring mutant ALK, including the most resistant G1202R
mutant.
A simple direct response PK-pharmacodynamic (PD) model-
ing analysis (Mager et al., 2003) was conducted to elucidate
the relationship between PF-06463922 plasma concentration,
inhibition of ALK phosphorylation, and suppression of tumor
growth. The Hill equation showed reasonable fits for both inhibi-
tion of ALK phosphorylation and antitumor efficacy (Figures
S3A–S3D). The PK, PD, TGI, and Hill equation parameters of
PF-06463922 from these studies are summarized in Tables S2
and S3, and the efficacious concentration (Ceff) values derived
from the Hill function analyses are summarized in Table S4. To
summarize, the Ceff values for tumor stasis (100% TGI) were
determined to be 6.5 nM in the H3122 EML4-ALKWT tumor
model, 38 nM in the H3122 EML4-ALKG1269A model, 68 nM
in the H3122 EML4-ALKL1196M model, and 165 nM in the 3T3
EML4-ALKG1202R model. The estimated half maximal effective
concentrations for inhibiting ALK phosphorylation were compa-
rable to the Ceff values for tumor stasis of each corresponding
ALK fusion (Table S4). The Ceff (68 nM free) determined for
the H3122 EML4-ALKL1196M model with PF-06463922 adminis-
tered by infusion is similar to the Ceff (51 nM free) determined
using the oral route (Yamazaki et al., 2014). The Ceff values for
maximum antitumor response for PF-06463922 correlated
closely with the estimated 90%maximal effective concentration
values for ALK phosphorylation inhibition in these tumors (Fig-
ures S3A–S3D and Table S4).
An oral dosing study in the H3122-EML4-ALKL1196M model
demonstrated significant tumor regression (35%) and greater
than 95% inhibition of ALK phosphorylation in the 10 mg/kg
twice daily (BID) group. The antitumor efficacy of the
10 mg/kg BID oral dosing schedule was similar to that of the
30 mg/kg once daily (QD) group (33% regression), and superior
to the 10 mg/kg QD group (3% tumor regression) (Figure S3E).
The 10 mg/kg BID group had lower unbound plasma maximal
concentration (Cmax) (392 nM) than either the 10 mg/kg
QD (1,636 nM) or the 30 mg/kg QD (3,193 nM) group,
indicating that the antitumor efficacy of PF-06463922 was not
driven by Cmax in this model (Table S2). Collectively, these
results indicate that near complete inhibition of ALK phosphory-
lation (>95%) with prolonged duration during the dosing interval
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Figure 2. PF-06463922 Potently Inhibits ALK Fusion Wild-Type and Mutant-Mediated Tumor Cell Survival
(A–C) Cell viability assays of H3122 EML4-ALKWT (A), H3122 EML4-ALKL1196M (B), and H3122 EML4-ALKG1269A (C) cells treated with the indicated doses of
crizotinib or PF-06463922 for 72 hr. Cell viability was assayed by Cell-Titer-Glo. For (A) to (C), values are presented as mean ± SEM (n = 3).
(D) IC50 values of PF-06463922, crizotinib, ceritinib, and alectinib on ALK phosphorylation in H3122 cell lines expressing EML4-ALK
WT, EML4-ALKL1196M, and
EML4-ALKG1269A. Values are presented as mean ± SEM (n = 3–7).
(E) Cleaved caspase-3/7 induction by PF-06463922 treatment in the three different H3122 cell models. Values are presented as mean ± SD (n = 3).
(F) Cell viability assay of the alectinib-resistant H3122 cell line (EML4-ALKV1180L) treated with the indicated doses of crizotinib, PF-06463922 or alectinib for 72 hr.
Values are presented as mean ± SEM (n = 6).
(G) Cell survival and ALK phosphorylation IC50 values of PF-06463922, crizotinib, ceritinib, and alectinib on crizotinib-resistant patient-derived cell line SNU2535
(EML4-ALKG1269A). Values are presented as mean ± SEM (n = 3–14).
(H) Cell viability assay of ceritinib-resistant patient-derived cell line MGH021-5 (SQSTM1-ALKG1202R) treated with the indicated doses of crizotinib, PF-06463922,
or alectinib for 7 days. Values are presented as mean ± SEM (n = 3).
(I) Cell viability assay of alectinib-resistant patient-derived cell line MGH056-1 (EML4-ALKI1171T) treated with the indicated doses of crizotinib, PF-06463922, or
alectinib for 72 hr. Values are presented as mean ± SEM (n = 3).
See also Figure S2.
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Figure 3. PF-06463922 ALK Target Inhibi-
tion PK/PD Relationships in ALK Fusion-
Driven Subcutaneous Tumor Xenograft
Models in Mice
(A–D) Mini-pump infusion study in H3122 model
expressing endogenous EML4-ALKWT (A), H3122
model expressing engineered EML4-ALKL1196M
(B), H3122 model expressing engineered human
EML4-ALKG1269 (C), and 3T3 model expressing
engineered human EML4-ALKG1202R (D). Tumor
sizes (left) and pALK level and PF-06463922
free plasma concentration (right) of each group
are indicated. ALK phosphorylation in tumors
was measured at the time of sacrifice following
the last tumor volume measurement. The tumors
were collected and processed immediately after
sacrifice. Tumor volumes, ALK phosphorylation,
and plasma concentration values are presented
as mean ± SEM (n = 8–12).
See also Figure S3 and Tables S2–S4.by PF-06463922 is necessary to achieve maximal tumor regres-
sion, and PF-06463922 is able to achieve this activity at a rela-
tively low dose.
PF-06463922 Drives Superior TGI In Vivo Compared
with Crizotinib
The in vivo efficacy of PF-06463922 was directly compared with
that of crizotinib in engineered H3122 models and patient-
derived cell lines. Consistent with in vitro data, PF-06463922
showed superior efficacy compared with crizotinib in tumor
xenografts derived from H3122 EML4-ALKWT (Figure S4A),74 Cancer Cell 28, 70–81, July 13, 2015 ª2015 Elsevier Inc.H3122 EML4-ALKL1196M (Figure 4A),
and H3122 EML4-ALKG1269A cells (Fig-
ure S4B). In parallel with tumor growth,
PF-06463922 inhibited ALK-mediated
signal transduction in tumor tissues
collected 3 hr following the final dose
of a 4-day treatment regimen to a greater
extent than crizotinib. Specifically,
ALK, AKT, ERK, STAT3, and S6 phos-
phorylation was significantly decreased
by PF-06463922 in the respective
H3122 EML4-ALK models (Figures S4C–
S4E). These data corresponded to
dose-dependent induction of cleaved
caspase-3 levels measured in H3122
EML4-ALKL1196M tumor samples from
mice treated with 3 and 10 mg/kg/day of
PF-06463922 (Figure 4B). Of note, in
H3122 EML4-ALKWT tumor-bearing
mice, PF-06463922 showed similar effi-
cacy in inhibiting tumor growth and ALK
phosphorylation compared with alectinib
(Figures S4A and S4C).
Two ALK-positive patient-derived cell
lineswere also used to evaluate the in vivo
antitumor efficacy of PF-06463922
against wild-type EML4-ALK. MGH051(EML4-ALKWT) (Figure 4C) was derived from a crizotinib-resis-
tant ALK-positive NSCLC patient (Friboulet et al., 2014).
MGH006 (EML4-ALKWT) (Figure S4F) was derived from a crizoti-
nib-naive ALK-positive NSCLC patient (Katayama et al., 2012).
Oral administration of PF-06463922 potently suppressed ALK
phosphorylation and led to substantial tumor regression of
these xenograft models (Figures S4G and S4H).
The antitumor efficacy of PF-06463922 in xenograft models
was durable. PF-06463922 suppressed subcutaneous tumor
growth longer than 170 days in both MGH051 (EML4-ALKWT)
(Figure 4C) and H3122-EML4-ALKG1269A (Figure 4D) and models
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Figure 4. PF-06463922 Antitumor Efficacy
in ALK Fusion-Driven Subcutaneous Xeno-
graft Tumor Models in Mice
(A) Subcutaneous tumor growth in the H3122
EML4-ALKL1196M tumor model treated with orally
dosed crizotinib 75mg/kg BID or PF-06463922 0.3
to 10 mg/kg BID for 13 days. Tumor volumes are
presented as mean ± SEM (n = 12).
(B) Activated caspase-3-positive cell numbers
following 3 days of oral BID administration of
PF-06463922 in the H3122-EML4-ALKL1196M
model (cf. Figure 4A). Values are expressed as
mean ± SEM (n = 7–9).
(C) Long-term subcutaneous tumor growth in
the EML4-ALKWT MGH051 crizotinib-resistant pa-
tient-derivedmodel treatedwithcrizotinib25mg/kg
QD or PF-06463922 10 mg/kg BID. The mice
treatedwith crizotinib were shifted to PF-06463922
after 107 days of treatment (arrow). Tumor volumes
are presented as mean ± SD (n = 5–12).
(D) Long-term subcutaneous tumor growth of
the H3122-EML4-ALKGG1269A tumors treated
with PF-06463922 subcutaneous pump infusion
at 11 mg/kg/day for 172 days. Tumor volumes are
presented as mean ± SEM (n = 5–12).
See also Figure S4.at drug concentrations predicted to be clinically achievable.
Moreover, PF-06463922 induced tumor regression in mice
bearing MGH051 tumors that relapsed on crizotinib (Figure 4C).
PF-06463922 Induced Superior Regression of
Intracranial EML4-ALK Tumors and Prolonged Mouse
Survival Compared with Other Clinically Available
ALK Inhibitors
Nearly 50% of ALK-positive NSCLC patients undergoing crizoti-
nib treatment exhibit brain metastasis as the first site of disease
progression, and in nearly 80% of these patients, systemic dis-
ease is under control (Camidge, 2013; Solomon et al., 2014b).
The physicochemical properties of PF-06463922 were specif-
ically optimized to maximize its CNS availability. PF-06463922
demonstrated 21% to 31% free brain drug exposure relative to
free plasma concentration in non-tumor-bearing rats and dogs
and is predicted to penetrate the intact BBB in humans (Johnson
et al., 2014).
To investigate the antitumor efficacy of PF-06463922 in an
NSCLC brain metastasis model, we conducted intracranial
xenograft studies with EML4-ALK-positive tumor models con-
taining either wild-type EML4-ALK (H3122 or MGH006 cells) or
the ALKL1196M gatekeeper mutation (H3122 EML4-ALKL1196M
cells). Tumor cells were engineered to express either firefly lucif-
erase or Gaussia luciferase (Gluc) in order to allow noninvasiveCancer Cell 28, 7monitoring of tumor growth in vivo by
either whole-body in vivo imaging sys-
tems (IVIS) or tail vein blood Gluc activity
measurement, respectively.
As shown by MRI (Figures 5A and 5B),
IVIS (Figures S5A–S5C) images, and
blood Gluc activity measurements over
time (Figure 5C), PF-06463922 demon-strated significant antitumor activity against H3122EML4-ALKWT
brain metastases that was superior to either crizotinib or alecti-
nib. In subcutaneous studies, H3122 (EML4-ALKWT) tumors
displayed similar sensitivity to PF-06463922 and alectinib (Fig-
ure S4A). However, although H3122 brain metastases relapsed
between 40 and 120 days after alectinib initiation, PF-06463922
treatment suppressed tumor growth in all mice for the duration
of the experiment (160 days). Interestingly, shifting the alecti-
nib-relapsed mice to PF-06463922 induced a second tumor
response in those animals, demonstrating that PF-06463922
has superior intracranial efficacy compared with alectinib
(Figure 5C). The suppression in brain metastasis growth by
PF-06463922 was consistent with better suppression of ALK
phosphorylation (Figure 5D). Immunohistochemistry analysis
indicated a significant reduction in the Ki67-positive tumor cell
number and mitotic index in brain xenografts from mice within
the 10 mg/kg BID treatment group (Figures S5C and S5D).
Consistent with the H3122 EML4-ALKWT brain metastasis
study, PF-06463922 dose-dependently regressed H3122
EML4-ALKL1196M brain metastases at 5, 10, and 20 mg/kg/day,
corresponding to median free brain drug concentrations of 35,
55, and 100 ng/g, respectively (Figures S5E and S5F). In
contrast, control-treated mice were euthanized, on average,
11 days after treatment initiation because of declining health
attributed to tumor burden.0–81, July 13, 2015 ª2015 Elsevier Inc. 75
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Figure 5. PF-06463922 Antitumor Efficacy in ALK Fusion-Driven Intracranial Tumor Models
(A) Representative magnetic resonance images showing regression of large established H3122 EML4-ALKWT intracranial tumors in mice following PF-06463922
infusion.
(B) Quantitation of brain tumor sizes following PF-06463922 treatment in the H3122 EML4-ALKWT intracranial model shown in (A). Values are presented as
mean ± SEM.
(C) Oral dosing of PF-06463922, crizotinib, and alectinib. Long-term brain orthotopic tumor growth of H3122 EML4-ALKWT cells expressing secreted luciferase
treated with crizotinib 50 mg/kg QD or alectinib 60 mg/kg QD or PF-06463922 10 mg/kg BID. The mice treated with alectinib were shifted to PF-06463922 at the
indicated times (blue arrows).
(D) PD analysis of H3122 EML4-ALKWT brain tumors treated for 3 days and collected 3 hr after last treatment.
(E and F) Brain tumor growth (E) and Kaplan-Meier survival curves (p < 0.0001) (F) of MGH006 EML4-ALKWT patient-derived cell line in mice treated orally dosed
with crizotinib 100 mg/kg QD or PF-06463922 10 mg/kg/day BID for 42 days.
(G) PD analysis of MGH006 brain tumors treated for 3 days and collected 3 hr after last treatment. Individual blood Gluc activity values are presented for each
mouse (n = 5–7 per group).
See also Figure S5.
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Figure 6. PF-06463922 Preclinical Pharma-
cology Profile
(A) Cell survival curves of Ba/F3 parental (left) or
EML4-ALKWT-expressing cells (right) following
treatment for 48 hr with crizotinib, alectinib,
or PF-06463922. Cell survival was assayed using
Cell-Titer-Glo. Values are presented as mean ±
SEM (n = 3).
(B) PF-06463922 preclinical pharmacology profile
and safety margin.
See also Figure S6.We hypothesized that the superior inhibition of brain metas-
tasis growth, attributed to better ALK kinase inhibition, was
due to two factors: the enhanced potency of PF-06463922
and/or its increased ability to cross the BBB. To determine which
mechanism attributed to its efficacy in our brain metastasis
model, we tested an ALK inhibitor, PF-06439015, that possesses
1.5-fold greater potency than PF-06463922 but has poor CNS
penetration (Huang et al., 2014; Johnson et al., 2014). Continued
subcutaneous infusion of PF-06463922 (6–12 mg/kg/day)
suppressed brain tumor growth better than PF-06439015
(36mg/kg/day) (Figure S5B). PK analysis from these studies indi-
cated that the brain free fraction of PF-06463922 (0.30 ± 0.13)
relative to free plasma concentration was >4-fold higher than
that of PF-06439015 (0.07 ± 0.02) in mice bearing intracranial
tumors. Similarly, better growth delay in the H3122 EML4-
ALKL1196M brain metastasis model was attributed to better
drug penetration, as PF-06439015 failed to control their growth
as brain tumor drug concentrations reached only 9.5 ng/g (Fig-
ures S5E and S5F).
Patient-derived MGH006 cells expressing Gluc were equally
sensitive to crizotinib and PF-06463922 in subcutaneous studies
(Figure S4F). When grown in the brain, however, PF-06463922Cancer Cell 28, 7suppressed MGH006 tumor growth
longer than crizotinib, leading to a signif-
icant improvement in survival (Figures
5E and 5F). Crizotinib delayed MGH006
brain metastasis growth roughly 3-fold
compared with control-treated mice, but
all mice were euthanized within 45 days
after treatment initiation because of
neurological defects consistent with
large CNS tumors. At this time point,
brain metastases from PF-06463922-
treated mice were barely detectable
and much smaller than when treatment
was initiated. Consistent with their
effects on brain metastasis growth, PF-
06463922 achieved better suppression
of ALK phosphorylation compared with
crizotinib (Figure 5G). Furthermore, we
observed reductions in total ALK levels
in both treatment groups, but particularly
after treatment with PF-06463922. It has
been previously reported that HSP90
binding to ALK-fusion proteins in cells is
disrupted by crizotinib treatment (Taipaleet al., 2013). This disruption may contribute to the reduction in
total ALK-fusion protein levels.
PF-06463922 Demonstrated a Broad Therapeutic
Window in Preclinical Studies
PF-06463922 demonstrated antitumor efficacy in both subcu-
taneous and brain orthotopic xenograft models harboring
oncogenic ALK fusions containing either wild-type ALK or crizo-
tinib-resistant ALKmutants at pharmacologically relevant doses.
PF-06469322 was well tolerated in mice (lack of significant
weight loss) at all doses used in our studies (Figure S6). This
safety profile is also reflected by in vitro cell assays. For example,
compared with other ALK inhibitors, PF-06463922 demon-
strated superior activity against ALK-fusion transformed Ba/F3
cells compared with other ALK inhibitors (Table S1), while
displaying less toxicity to parental Ba/F3 cells (IC50 > 10 mM)
(Figure 6A). This finding is likely due to its high level of selectivity
(Johnson et al., 2014).
The lack of toxicity of PF-06463922 in Ba/F3 cells, in combi-
nation with its superior potency, suggests that this compound
could achieve a strong preclinical safety margin. The preclinical
safety profile of PF-06463922 was characterized through0–81, July 13, 2015 ª2015 Elsevier Inc. 77
single- and repeat-dose studies of up to 1 month in duration in
rats and dogs, as well as safety pharmacology and genetic
toxicity studies. The nonclinical safety findings related to PF-
06463922 were identified at reasonable exposure margins
above the Ceff and represent toxicities that can be monitored
and are reversible following a 1 month treatment-free period
in rat and dog studies. PF-06463922 achieved a greater than
100-fold therapeutic index when comparing its Ceff (tumor sta-
sis) in the EML4-ALK subcutaneous tumor growth model to
its maximal tolerated dose (MTD) in both rats and dogs. The
Ceff values derived from our in vivo studies are summarized
in Table S4. It is worth mentioning that PF-06463922 achieved
a maximal effect for either ALK target inhibition or tumor
regression in each of the tested efficacy models at exposure
levels that are well below the MTD generated from 1 month
dog or rat safety studies (Figure 6B). Because PF-06463922
is a brain-penetrable compound, the potential for adverse
CNS effects were tested in repeated dose safety studies as
well as in the rat contextual renewal model. No CNS-mediated
signals were observed in these studies. Furthermore, the
functional observation battery (FOB) assessment was included
in the 1 month repeated dose study in the rat (data not shown).
FOB is a series of noninvasive observational and interactive
measures of CNS and automatic system function (e.g., body
temperature, pupil response, gait, locomotor activity). No FOB
effects were identified, despite achieving plasma exposures
60-fold higher than the predicted minimal efficacious exposure
in humans (51 nM free), defined as the free compound concen-
tration needed to achieve tumor stasis in the H3122 EML4-
ALKL1196M model.
DISCUSSION
The discovery of oncogenic ALK fusions and the development
of ALK targeted therapies, such as crizotinib, have transformed
the course of disease for patients with ALK-driven cancers,
particularly those with NSCLC. Patients derive significant benefit
from either crizotinib or the second-generation inhibitors alecti-
nib and ceritinib. However, the majority of patients invariably
relapse, and limited treatment options remain after relapse.
Here we report preclinical data on PF-06463922, a next-gen-
eration ALK inhibitor that is currently in a phase 1 and 2 clinical
trial (ClinicalTrials.gov identifier NCT01970865) for ALK or
ROS1 fusion-positive NSCLC. In a variety of different ALK
inhibitor resistant models, PF-06463922 demonstrated broad
activity across ALK resistant mutations, including G1202R,
which is the most refractory mutation identified to date.
G1202R has rarely been reported in the setting of crizotinib
resistance but is emerging as a common resistant mutation to
the second-generation ALK inhibitors ceritinib (Friboulet et al.,
2014) or alectinib (Ignatius Ou et al., 2014). This is consistent
with our preclinical studies showing that G1202R confers broad
resistance to first-and second-generation ALK inhibitors.
Although crizotinib has shown clinical activity against brain
metastases, the CNS is a common site of relapse for patients
on crizotinib (Costa et al., 2013, 2015; Solomon et al., 2014a,
2014c). Mechanisms of resistance in the CNS to crizotinib
have not been studied in detail, but one plausible mechanism
is the inability of crizotinib to achieve therapeutic concentrations78 Cancer Cell 28, 70–81, July 13, 2015 ª2015 Elsevier Inc.in the CNS compartment. Consistent with this notion, a case
report showed low levels of crizotinib in the cerebrospinal fluid
of a patient who had relapsed with brain metastases (Costa
et al., 2011). Poor brain penetration of crizotinib is likely due to
its high efflux by P-glycoprotein (PGP) (Johnson et al., 2014).
Second-generation ALK inhibitors have shown moderate CNS
activity, including patients who have relapsed on crizotinib
(Gadgeel et al., 2014). Similar to crizotinib, ceritinib is a PGP
substrate and has limited brain penetration (Shaw et al.,
2014b) and therefore responses to ceritinib likely reflect its
increased potency. Alectinib, on the other hand, is not a PGP
substrate and is associated with an intracranial response rate
of 52% (Gadgeel et al., 2014). Nevertheless, patients treated
with either ceritinib or alectinib still relapse with brain metasta-
ses, highlighting the need for a more potent inhibitor with
increased CNS availability that, ideally, is not a substrate for
PGP. PF-06463922 was specifically designed and optimized to
efficiently penetrate the BBB, and as a result it showed 30%
CNS availability in multiple preclinical species. We successfully
mimicked the clinical situation in mouse models and showed
that ALK fusion tumors, sensitive to crizotinib when growing
subcutaneously, were resistant when growing in the brain
parenchyma. Furthermore, PF-06463922 demonstrated supe-
rior efficacy to after alectinib relapse in our murine models of
brain metastasis. PF-06463922 regressed intracranial tumors
at doses much lower than the MTD in our preclinical studies.
In contrast, a potent ALK inhibitor with low CNS availability
(6%) failed to sustain TGI in the same intracranial tumor model,
suggesting penetration into the brain metastasis plays a major
role in the activity of PF-06463922. Although PF-06463922 pro-
vides hope that it will overcome brain metastases that develop
in patients who relapse to first- and second-generation ALK in-
hibitors, data from the ongoing phase 1 study of PF-06463922
will be necessary to evaluate the CNS activity of PF-06463922
in humans, as preclinical studies may not predict brain penetra-
tion in humans.
The potency and safety profile, in combination with the pene-
tration into the CNS, of PF-06463922 provides an opportunity to
address both acquired and pharmacological mechanisms of
drug resistance. Preclinical studies suggest a favorable preclin-
ical safety window for PF-06463922 consistent with the ability
to treat patients with drug exposures high enough to inhibit
the most recalcitrant G1202R mutant and to reach therapeutic
levels in the CNS. Preclinical studies are not always capable of
predicting clinical toxicity, so data from the ongoing phase 1
study of PF-06463922 will be critical in understanding the safety
margin that PF-06463922 can achieve in humans.
The most immediate impact of PF-06463922 may be on
patients in whom previous ALK TKIs have failed, not only in
systemic disease but also with brain metastases. Given that
PF-06463922 is the most potent and brain-penetrable inhibitor
that we tested in our models, whether it should be used as front-
line treatment is an intriguing question that awaits clinical inves-
tigation. For example, could the frontline use of PF-06463922
lead to more durable responses than sequential therapy in the
clinic, as suggested by the sustained responses seen with
PF-06463922 in preclinical studies? Finally, if the safety and
efficacy of PF-06463922 are confirmed in the clinic, PF-
06463922 may serve as an ideal backbone for combination
therapies aimed at overcoming and even preventing the emer-
gence of resistant clones.EXPERIMENTAL PROCEDURES
Enzyme Assays and Compounds
Recombinant human wild-type and mutant ALK kinase domain proteins
(amino acids 1093–1411) were produced in house using baculoviral expres-
sion, pre-activated via auto-phosphorylation with MgATP, and assayed
for kinase activity using a microfluidic mobility shift assay. The reactions
contained 1.3 nM wild-type ALK or 0.2 to 10 nM mutant ALK (appropriate
to produce 15%–20% phosphorylation of peptide substrate after 1 hr
reaction), 3 mM 5-FAM-KKSRGDYMTMQIG-CONH2, 5 mM MgCl2, and the
Km-level of ATP in 25 mM HEPES (pH 7.1). The Ki values were calculated
by fitting the percentage conversion to a competitive inhibition equation
(GraphPad Prism; GraphPad Software). PF-06463922 and PF-06439015
were synthesized as described in Huang et al. (2014) and Johnson et al.
(2014), respectively, and PF-02341066 as described in Cui et al. (2011).
The physical properties of PF-06463922 were specifically optimized to
maximize CNS availability by controlling molecular weight, lipophilicity, and
hydrogen bond donor count.
Cell Culture and Reagents
NCI-H3122 human NSCLC cells were licensed from the National Institutes
of Health (NIH). Karpas299 and NIH 3T3 cells were purchased from American
Tissue Culture. BaF3 cells were obtained from DSMZ. NCI-H3122 and
NCI-H2228 are human lung adenocarcinoma cell lines harboring the
EML4-ALK fusion protein variant 1 (V1) and variant 3 (V3a/b), respectively.
The SNU2535, MGH056-1, and MGH021-5 NSCLC cell lines were derived
from crizotinib-, alectinib-, or ceritinib-relapsed patients and harbor the
mutant ALK fusion proteins G1269A, I1171T, and G1202R, respectively.
MGH006, MGH051-1, MGH021-5, and MGH056-1 were maintained as
previously described (Friboulet et al., 2014; Katayama et al., 2012, 2014;
Kim et al., 2013). Cell culture reagents were obtained from Life Technologies.
Cells were maintained at 37C in a humidified atmosphere with 5% to
10% CO2.
Engineered Cell Line Generation
The target of interest was first cloned into the retroviral vector pMSCV puro or
pMSCVhygro. The retroviruses carrying recombinant genes were produced in
293T cells by co-transfection with the pMSCV vectors and the packaging
plasmid pCL10A1. The retroviral supernatants were used to transduce NCI-
H3122, NIH 3T3, or BaF3 parental cells, and pooled populations were selected
with 2 mg/l puromycin or 50 mg/l hygromycin for 5 days.
Cell-Based Kinase Phosphorylation ELISAs
Cells were seeded in 96-well plates in growth media with 0.5% fetal bovine
serum and incubated overnight. Compounds were diluted in media without
serum, added to the cells, incubated for 1 hr, and then removed by aspirating
the media by vacuum suction. Cell lysates were generated and the phospho-
ALK (Tyr1604) levels were determined by using the PathScan Phospho-ALK
(Tyr1604) Chemiluminescent Sandwich ELISA Kit (Cell Signaling) or PathScan
Total ALK Chemiluminescent Sandwich ELISA Kit (Cell Signaling), as
described in the manufacturer’s protocol. IC50 values were calculated by con-
centration-response curve fitting using a four-parameter analytical method.
This phospho-ALK ELISA was also used to determine phosphor-ALK levels
in the protein extracts from xenograft tumor samples.
Cell Proliferation Assay
Cells were seeded in 96-well plates in growth media containing 10% fetal
bovine serum (FBS) and cultured overnight at 37C. The following day, serial
dilutions of PF-06463922 or appropriate controls were added to the desig-
nated wells, and cells were incubated at 37C for 72 hr. A Cell Titer Glo assay
(Promega) was then performed to determine the relative cell numbers. IC50
values were calculated by concentration-response curve fitting using a four-
parameter analytical method.Cell Caspase-3/7 Activity Assay
Cells were seeded in 96-well plates at 15,000 cells/well in RPMI media supple-
mented with 0.5% FBS (Assay Media) and allowed to adhere overnight at
37C. The following day, 10 mM PF-06463922 was serially diluted in DMSO,
and the DMSO dilutions were further diluted in Assay Media and added to
the designated wells resulting in a range of serially diluted concentrations of
PF-06463922 in the media with 0.5% serum and 0.1% DMSO. The cells
were incubated for 24 hr, and the caspase-3/7 activity was measured using
the Caspase-Glo 3/7 Assay Kit (Promega), as described in the manufacturer’s
protocol. IC50 values were calculated by concentration-response curve fitting
using a four-parameter analytical method.
Animals
Female nu/nu mice aged 5 to 8 weeks were obtained from Charles River.
Animals were maintained under clean-room conditions in sterile filter-top
cages with Alpha-Dri bedding and housed on HEPA-filtered ventilated racks.
Animals received sterile rodent chow and water ad libitum. All animal proce-
dures were performed in compliance with the Institute for Laboratory Animal
Research Guide for the Care and Use of Laboratory Animals and the Public
Health Service Policy on Human Care of Laboratory Animals. Experiments
were approved by the Animal Care and Use Committee at Pfizer La Jolla
and by the Institutional Animal Care and Use Committee of Massachusetts
General Hospital.
Drug Administration
In all tumor xenograft studies, the compound of interest was administered
either orally at 5 to 10 ml/kg using sterile 20-gauge feeding needles (Popper
and Sons) or with a subcutaneous Alzet mini-pump (Durect) infusion.
Subcutaneous Tumor Model
The cells were supplemented with 50%Matrigel (BD Biosciences) to facilitate
tumor take. Cells (5 3 106 in 100 ml) were implanted subcutaneously into the
hind flank region of themouse and allowed to grow to the designated size prior
to the administration of compound for each experiment. Tumor size was
determined by measurement with electronic calipers, and tumor volume was
calculated as length 3 width2 3 0.4.
Intracranial Tumor Model
For injection into the brain, the head of the mouse was fixed with a stereotactic
apparatus, and the skull over the left hemisphere of the brain was exposed via
skin incision. Using a high-speed air-turbine drill (CH4201S; Champion Dental
Products) with a burr tip size of 0.5 mm in diameter, three sides of a square
(2.5 mm in length, each side) were drilled through the skull until a bone flap
became loose. Using blunt tweezers, the bone flap was pulled back, exposing
the brain parenchyma. One hundred thousand cancer cells, diluted in 1 ml PBS,
were stereotactically injected into the left frontal lobe of the mice. The bone
flap was then placed back into position in the skull and sealed using histocom-
patible cyanoacrylate glue, and the skin atop the skull was sutured closed.
Brain metastatic tumor growth was measured through the use of Gluc, an
in vivo secreted reporter expressed by tumor cells and measured in the
peripheral blood. In similar models, the blood Gluc activity directly correlated
with tumor volume (Kodack et al., 2012).
MRI Study
Magnetic resonance images were acquired with a Bruker 7.0 T scanner with
an Avance II console using a 72 mm inside diameter linear birdcage resonator
for transmission and a two-element surface coil array for local reception.
Pre- and post-contrast T1-weighted fast spin-echo images were acquired.
While in the scanner, the temperature and respiratory trace of each mouse
were monitored continuously. The isoflurane-oxygen mixture (1.4%–2.0%)
was adjusted on the basis of the respiratory rate. The mouse temperature
was stabilized by forced-air heating with automatic feedback from a rectal
temperature probe. Before post-contrast scans, mice were injected with
gadolinium. Injections were timed such that image acquisition coincided
with a period of stable tumor contrast, as determined in a pilot study. Tumor
volume was calculated by manual segmentation of T1-weighted images using
ImageJ software (NIH).Cancer Cell 28, 70–81, July 13, 2015 ª2015 Elsevier Inc. 79
Ex Vivo Target Modulation (PK/PD) Studies
For tissue and plasma processing for PK/PD studies, mice were humanely
euthanized, blood and brain tissue samples were collected for PK analysis,
and tumors were resected for PD analysis. Plasma and brain samples were
analyzed for PF-06463922 concentration using liquid chromatography mass
spectrometry analysis. Resected tumors were snap-frozen and pulverized
on a liquid nitrogen cooled cryomortar and pestle, and lysed in cold 1X Cell
Lysis Buffer (Cell Signaling Technologies). Proteins were extracted from
tumor lysate, and protein concentrations were determined using a BSA
assay (Pierce). The level of phosphorylated ALK in each tumor sample was
determined using the capture ELISA or western blotting method.
Immunoblotting
The immunoblotting method was also used to determine relative kinase
phosphorylation status and total protein levels in cells and tumor tissues for
the protein of interest. Extracted protein samples from cells or tumor lysates
were separated by SDS-PAGE and transferred to nylon membranes, and
immunoblotting hybridizations for the proteins of the interest were performed
using the corresponding antibodies. Phospho-ERK (T202/Y204), ERK, S6,
phospho S6, phospho-AKT (S473 and T308), AKT, phospho-ALK (Y1282/
1283), and ALK antibodies were obtained from Cell Signaling Technology.
GAPDH was purchased from Millipore.
Statistics
Sample size for in vivo TGI studies was estimated to be about n = 8 to 12 per
group to ensure 80% power to capture 70% TGI in a one-sided test on the
basis of variability estimate from historical data. Animals were randomized
into different treatment groups stratified on their initial tumor size, so the
average tumor size for each group was similar at baseline. Standard inclusion
and exclusion criteria were used whereby animals were excluded only in
rare occasions (such as death) after randomization. Investigators were not
blinded to treatment assignment. Because of skewed distribution of the
tumor volume data, ANOVA models were fit to the rank-transformed tumor
volume. Individual comparisons between treatment groups and vehicle group
or among the treatment groups were assessed withone1-sided least signifi-
cant difference tests and, all under the ANOVA model for ranks.
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